Biogena Group Invest AGWBO:BIO -5.41%66 EBITDA Margin % is 84.62% as of Jan. 2026, which is 11% below its 10-year median of 95.32. GuruFocus rates WBO:BIO with a GF Score™ of 66/100 and a GF Value™ of €3.45 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,952 Consumer Packaged Goods companies, Biogena Group Invest AG ranks better than 98.51% on this metric.
Biogena Group Invest AG (WBO:BIO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biogena Group Invest AG EBITDA Margin % Related Terms
Biogena Group Invest AG EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:BIO vs KHC, GIS, HRL: EBITDA Margin % Comparison
For the Packaged Foods subindustry, Biogena Group Invest AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogena Group Invest AG EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biogena Group Invest AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogena Group Invest AG (WBO:BIO) has a EBITDA Margin % of 84.62% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biogena Group Invest AG and its competitors. This is 11% below median its historical median of 95.32. Over the past decade, Biogena Group Invest AG's EBITDA Margin % has ranged from 45.90 to 246.83. According to the industry distribution chart, Biogena Group Invest AG ranks #29 out of 1952 companies in the Consumer Packaged Goods industry, placing it in the top 1.5%.
Is Biogena Group Invest AG's EBITDA Margin % too high?
Biogena Group Invest AG's current EBITDA Margin % of 84.62% is 11% below median its 10-year median of 95.32. Over the past 10 years, this metric has ranged from a low of 45.90 to a high of 246.83. The Consumer Packaged Goods industry median EBITDA Margin % is 8.98. Biogena Group Invest AG's value of 84.62% is 842.3% above this industry median. Based on the distribution chart, Biogena Group Invest AG ranks #29 out of 1952 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Biogena Group Invest AG has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biogena Group Invest AG ranks #29 out of 1952 companies for EBITDA Margin %. This places Biogena Group Invest AG in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 8.98. Biogena Group Invest AG's value of 84.62% is 842.3% above this benchmark. Historically, Biogena Group Invest AG's own EBITDA Margin % has ranged from 45.90 to 246.83 over the past decade. While the company's 10-year median is 95.32 vs. the industry median of 8.98, Biogena Group Invest AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.98, based on 1,952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogena Group Invest AG's current EBITDA Margin % of 84.62% is 842.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biogena Group Invest AG and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogena Group Invest AG's current EBITDA Margin % is 84.62%, which is 11% below median its own 10-year median of 95.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.45, compared to a current price of €4.20 — trading 21.7% above its estimated fair value. The current EBITDA Margin % is 84.62%, which is 11% below median its 10-year median of 95.32 and 842.3% above the Consumer Packaged Goods industry median of 8.98. Biogena Group Invest AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current EBITDA Margin % is 84.62% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €4.20 is trading 21.7% above its estimated GF Value™ of €3.45.
GuruFocus considers Biogena Group Invest AG to be Modestly Overvalued.
Key valuation signals for WBO:BIO:
EBITDA Margin %: 84.62% (11% below median its 10-year median of 95.32)
GF Value™: €3.45 vs. price of €4.20 (21.7% above fair value)
Industry Position: 842.3% above the Consumer Packaged Goods median (#29 of 1952)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
66GF Score
Get the complete analysis for WBO:BIO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 